Fig. 5: MV130 prophylactic treatment prevents allergic sensitization and HDM-induced eosinophilic airway inflammation, conferring protection up to 9 weeks after treatment discontinuation. | Nature Communications

Fig. 5: MV130 prophylactic treatment prevents allergic sensitization and HDM-induced eosinophilic airway inflammation, conferring protection up to 9 weeks after treatment discontinuation.

From: A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease

Fig. 5

a Schematic representation of the prophylactic treatment with MV130 or vehicle, resting period (1, 2, 4 or 9 weeks) and following HDM-induced asthma model. Two control groups without sensitization were included, MV130 group receiving PBS in the sensitization and challenge and MV130 during immunization and a PBS group receiving only PBS; i.n., intranasal. b Serum total IgE, HDM-specific IgG1 levels (n = 3–9 mice from each group; 2 independent experiments). c Quantification of total cell numbers of different populations in bronchoalveolar lavage fluid (BALF) as determined by flow cytometry (n = 3–9 mice from each group; 2 independent experiments). d Quantification of total cell numbers of eosinophils, e B cells and f Th2 cells in BALF (n = 3–9 mice from each group; 2 independent experiments). Values are mean ± SEM. Statistical significance was determined using unpaired Two-way ANOVA (b) and unpaired One-way ANOVA (c–f) tests: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Exact p values and source data are available in the Source Data file.

Back to article page